VTCN1 and neoplasm: Whether targeting B7-H4 in vivo will lead to the elimination of CSCs/CICs and, subsequently, cancer eradication remains uncertain and thus, more studies are required to unleash the potential utility of B7-H4 as a biomarker for CSCs/CICs or tumor aggressiveness.